Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Abstract Objectives To identify a therapeutic target interval for certolizumab pegol drug levels and examine the influence of anti-drug antibodies in patients with inflammatory joint diseases. Methods Certolizumab pegol and anti-drug antibody levels were measured in serum samples collected after 3 m...

Full description

Bibliographic Details
Main Authors: Johanna Elin Gehin, Guro Løvik Goll, David John Warren, Silje Watterdal Syversen, Joseph Sexton, Eldri Kveine Strand, Tore Kristian Kvien, Nils Bolstad, Elisabeth Lie
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Arthritis Research & Therapy
Subjects:
TNF-inhibitors
Certolizumab pegol
Serum drug levels
Anti-drug antibodies
Inflammatory joint diseases
Axial spondyloarthritis
Online Access:https://doi.org/10.1186/s13075-019-2009-5

Internet

https://doi.org/10.1186/s13075-019-2009-5

Similar Items